Vor Biopharma Inc. (NASDAQ:VOR) Given Consensus Rating of “Moderate Buy” by Analysts

Vor Biopharma Inc. (NASDAQ:VOR) has received a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $42.25.

A number of brokerages have commented on VOR. Wells Fargo & Company began coverage on Vor Biopharma in a research note on Thursday, March 19th. They issued an “overweight” rating and a $30.00 target price on the stock. Wedbush upped their price target on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a research note on Thursday, May 14th. Wall Street Zen downgraded Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Vor Biopharma in a research note on Monday, May 18th. Finally, Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th.

Insider Activity

In other news, Director Ra Capital Management, L.P. sold 165,150 shares of the company’s stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares in the company, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 3,002,903 shares of company stock worth $49,412,176. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Vor Biopharma

Several large investors have recently made changes to their positions in VOR. RA Capital Management L.P. boosted its stake in shares of Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. boosted its stake in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after acquiring an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new stake in shares of Vor Biopharma during the 4th quarter worth about $33,275,000. Paradigm Biocapital Advisors LP bought a new stake in shares of Vor Biopharma during the 4th quarter worth about $22,890,000. Finally, NEXTBio Capital Management LP acquired a new position in shares of Vor Biopharma during the 4th quarter worth about $13,080,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Stock Performance

Shares of NASDAQ VOR opened at $14.49 on Friday. The business’s 50-day moving average price is $14.84 and its two-hundred day moving average price is $14.12. Vor Biopharma has a one year low of $4.29 and a one year high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 EPS for the quarter. On average, sell-side analysts predict that Vor Biopharma will post -2.51 EPS for the current year.

About Vor Biopharma

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).